NUCLIDIUM Closes CHF 79 Million (EUR 84 Million) Series B Financing to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform

NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced the successful closing of its Series B financing round, raising CHF 79 million (EUR 84 million). The round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR (Intesa Sanpaolo Group), with participation from DeepTech & Climate Fonds (DTCF), Bayern Kapital, Vives Partners, Eurazeo, NRW.BANK and HighLight Capital, as well as existing investors. The proceeds will be used to advance the clinical development of NUCLIDIUM’s Copper-61/Copper-67 (⁶¹Cu/⁶⁷Cu) theranostic pipeline across multiple oncology indications. In parallel, the company will expand its production and manufacturing capabilities through a global production network.

Walder Wyss advised Angelini Ventures, Kurma Partners and Wellington Partners as co-lead investors on the Series B financing round. The team included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital), Karina Tschon (Managing Associate, Corporate/M&A and Venture Capital), Celine Weber (Managing Associate, Life Sciences and Health Care), Christoph Burckhardt (Associate, Corporate/M&A and Venture Capital), Oerjan Wickart (Associate, Corporate/M&A and Venture Capital) as well as Bojan Momic (Associate, Employment) and Frederik Weber (Associate, Employment).